High risk disease - from definition to treatment

ESH eLearning, Jonathan KEATS, 261675

Double hit also in myeloma? The role of genome sequencing

ESH eLearning, Gareth MORGAN, 261682

CML diagnosed in a pregnant woman

ESH eLearning, Jane APPERLEY, 272261

Pregnancy in CML and MPN

ESH eLearning, Jane APPERLEY, 272260

Case-based lecture: IFN/TKI combination and IFN maintenance therapy in CML

ESH eLearning, Andreas Buchert, 272259

Case-based lecture: CML in blast crisis

ESH eLearning, Massimo BRECCIA, 272258

Finding the right time to start systemic therapy in PV after multiple phlebotomies

ESH eLearning, Claire Harrison, 272262

Asciminib: Results from the phase I study and perspectives of allosteric BCR-ABL1 inhibition

ESH eLearning, Delphine Rea, 272263

The young patient with myelofibrosis: To transplant or not to transplant

ESH eLearning, Claire Harrison, 272250

Case-based lecture: Management of blast phase MPN

ESH eLearning, John Mascarenhas, 272247

TKI therapy in a patient with CSFR3 mutated MPN

ESH eLearning, Jeffrey Tyner and Jason Gotlib, 272256

Case-based lecture: Diagnosis and risk stratification of MF

ESH eLearning, Alessandro Vannucchi, 272245

Case-based lecture: Management of myelofibrosis: excluding stem cell transplant

ESH eLearning, Ruben Mesa, 272246

Case-based lecture: CML as an emergency: Initial management of patients with high tumour load

ESH eLearning, Andreas Hochhaus, 272251

Case-based lecture: Diagnosis and management of a CML and CNL

ESH eLearning, Jeffrey Tyner, 272248

Familial MPN: diagnosis and treatment

ESH eLearning, Jean-Christophe Ianotto, 272249

To continue or to discontinue treatment in a CML patient in deep molecular response

ESH eLearning, Andreas Buchert, 272255

Case-based lecture: Role of baseline cytogenetics and prognostic scores

ESH eLearning, Dragana Milojkovic, 272252

Case-based lecture: Milestones - Management of suboptimal response

ESH eLearning, Jeroen Janssen, 272254

Case-based lecture: Role of concomitant disease and drug therapy for TKI selection

ESH eLearning, Delphine Rea, 272253

Myelofibrosis: progression vs drug failure

ESH eLearning, Ruben Mesa, 272244

Diagnosis and treatment initiation of CML

ESH eLearning, Andreas Hochhaus, 272243

NO

ESH eLearning, John Mascarenhas, 272242

YES

ESH eLearning, Alessandro Vannucchi, 272241

Molecular predictors of outcome in MPN

ESH eLearning, Jyoti Nangalia, 272240

Case-based lecture: Management of essential thrombocythaemia

ESH eLearning, Claire Harrison, 272239

Case-based lecture: Diagnosis and management of non-PV erythrocytosis

ESH eLearning, Mary Frances McMullin, 272238

New Insights into the early-stage bone colonization of disseminated cancer cells

ESH eLearning, Xiang H.F. Zhang, 261707

Molecular regulation and heterogeneity in quiescence exit of human haematopoietic stem cells

ESH eLearning, Elisa Laurenti, 261706

Subversion of systemic glucose metabolism as a mechanism to support the growth of leukaemia cells

ESH eLearning, Haobin Ye, 261705

Fatty acid metabolism and bone marrow adipocytes in AML

ESH eLearning, Yoko Tabe, 261704

The HSC niche in aging

ESH eLearning, Hartmut Geiger, 263172

Optimal cost/safety/efficacy/QOL ration

ESH eLearning, Jean-Luc Harousseau, 233982

Real-world evidence –What is it and what can it tell us?

ESH eLearning, Kwee Yong, 233981

How to judge the value of a clinical trial: HR, median PFS, p-value

ESH eLearning, Robert Hills, 233980

POEMS syndromes

ESH eLearning, Arnaud Jaccard, 233979

Genomic landscape of Waldenström’s macroglobulinemia

ESH eLearning, Steven Treon, 233978

New generation sequencing in multiple myeloma

ESH eLearning, Nikhil Munshi, 233973

Future combinations for the treatment of MM

ESH eLearning, Kenneth C. Anderson, 233977

Adoptive cell therapy in multiple myeloma

ESH eLearning, Jesus Berdeja, 233976

New drugs, new immune therapies, new targeted therapies

ESH eLearning, Enrique Ocio, 233975

When and how to treat first relapse according to the guidelines

ESH eLearning, Meletios Dimopoulos, 233974

Early detection and intervention in myeloma: a critical point

ESH eLearning, Jesús San Miguel, 234024

Continuous vs. fixed duration therapy for multiple myeloma?

ESH eLearning, Jesús San Miguel, 234025

Future treatment combinations for myeloma

ESH eLearning, Kenneth Anderson, 234026

MRD detection in myeloma: approval of NGS assay & questions for the clinic

ESH eLearning, Kenneth Anderson, 234027

Frontline transplant-ineligible MM treatment

ESH eLearning, Kwee Yong, 234028

Combining bortezomib and lenalidomide-based regimens for frontline MM

ESH eLearning, Kwee Yong, 234029

Real world evidence: what is it and what can it tell us?

ESH eLearning, Kwee Yong, 234030

How should smoldering multiple myeloma be monitored?

ESH eLearning, María-Victoria Mateos, 234031

From MGUS to MM: Do all clones take the same road?

ESH eLearning, Madhav Dhodapkar, 233965

Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma

ESH eLearning, María-Victoria Mateos, 234033

Opinion: EU approval of daratumumab plus VMP for frontline transplant-ineligible multiple myeloma

ESH eLearning, María-Victoria Mateos, 234034

Plasma cell leukemia and extramedullary disease in multiple myeloma

ESH eLearning, Niels van de Donk, 234035

Daratumumab in myeloma update: expanding indications

ESH eLearning, Niels van de Donk, 234036

A novel mechanism of action for daratumumab in myeloma

ESH eLearning, Niels van de Donk, 234037

CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079

ESH eLearning, Niels van de Donk, 234038

MRD negativity using deep sequencing is a major prognostic factor in myeloma

ESH eLearning, Nikhil Munshi, 234039

MRD sequencing test approved for MM in the US

ESH eLearning, Nikhil Munshi, 234040

Genomics shed light on targeted treatment for myeloma

ESH eLearning, Nikhil Munshi, 234041

Frontline treatment of transplant-ineligible MM: a changing landscape

ESH eLearning, Noopur Raje, 234042

Quadruplet regimens and antibodies for newly diagnosed multiple myeloma

ESH eLearning, Noopur Raje, 234043

CAR T-cells for myeloma: an update

ESH eLearning, Noopur Raje, 234044

PVX-410 vaccine for smoldering myeloma

ESH eLearning, Noopur Raje, 234045

Precision medicine in multiple myeloma: BRAF, NRAS, KRAD, t(11;14)

ESH eLearning, Noopur Raje, 234046

Judging the value of a clinical trial in hem-onc

ESH eLearning, Robert Hills, 234047

Opinion: value of MRD as an endpoint in hem-onc clinical trials

ESH eLearning, Robert Hills, 234048

UK NCRI AML17 trial update: everolimus addition for consolidation

ESH eLearning, Robert Hills, 234049

MRD and disease eradication in myeloma

ESH eLearning, Jesús San Miguel, 234023

Toxicity profile for CAR T-cells in multiple myeloma

ESH eLearning, Jesus Berdeja, 234022

CAR T-cells for multiple myeloma: update & what's in store for ASH 2018

ESH eLearning, Jesus Berdeja, 234021

Opinion: MRD sequencing test approval in multiple myeloma

ESH eLearning, Irene Ghobrial, 234020

Smoldering multiple myeloma: what is the current definition & new screening programme

ESH eLearning, Irene Ghobrial, 234019

Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells

ESH eLearning, Heinz Ludwig, 234018

Treatment sequencing in multiple myeloma: a multitude of options

ESH eLearning, Heinz Ludwig, 234017

Double-blind trial of denosumab vs. zoledronic acid for bone disease in NDMM

ESH eLearning, Evangelos Terpos, 234016

Real world data for len/dex in second-line myeloma: what does this tell us?

ESH eLearning, Evangelos Terpos, 234015

Real world data: bortezomib-based therapy for R/R myeloma

ESH eLearning, Evangelos Terpos, 234014

The evolving imaging of multiple myeloma

ESH eLearning, Evangelos Terpos, 234013

Are BCL2 and MCL1 inhibitors the key against myeloma?

ESH eLearning, Enrique Ocio, 234012

Immunotherapeutics against multiple myeloma: it's all about BCMA

ESH eLearning, Enrique Ocio, 234011

A host of promising agents for myeloma: melflufen, filanesib, trametinib, selinexor

ESH eLearning, Enrique Ocio, 234010

Where will we be in MM management 5 years from now?

ESH eLearning, Elena Zamagni, 234009

What is the role of PET/CT in myeloma management?

ESH eLearning, Elena Zamagni, 234008

Investigating vaccines for hem-onc: key questions

ESH eLearning, David Avigan, 234007

Dendritic cell vaccine for MM: trial updates with maintenance & checkpoint inhibitor pidilizumab

ESH eLearning, David Avigan, 234006

Smoldering myeloma treatment landscape & MRD negativity

ESH eLearning, Annemiek Broijl, 234005

Treatment options for high-risk myeloma

ESH eLearning, Annemiek Broijl, 234004

How do we define a ‘cure’ in myeloma?

ESH eLearning, Annemiek Broijl, 234003

Vaccines to prevent progression or relapse in multiple myeloma

ESH eLearning, Ann van de Velde, 234002

MRD as a response assessment in elderly multiple myeloma

ESH eLearning, Alessandra Larocca, 234001

Geriatric assessment in multiple myeloma: is it required?

ESH eLearning, Alessandra Larocca, 234000

Induction therapy: triplet, quadruplet?

ESH eLearning, Philippe Moreau, 233972

Ongoing trials for newly diagnosed patients not eligible for stem cell transplantation, and frontline treatment when new drugs are not available

ESH eLearning, Kwee Yong, 233971

European guidelines

ESH eLearning, Sonja Zweegman, 233970

Geriatric assessment: is it required?

ESH eLearning, Alessandra Larocca, 233969

Primary plasma cell leukaemia and extramedullary disease

ESH eLearning, Niels W.C.J. van de Donk, 233968

Genetics and risk assessment (including clonal evolution and clinical implications in terms of risk assessment)

ESH eLearning, Hervé Avet-Loiseau, 233967

Leukemic stem cells modulate the bone marrow microenvironment

ESH eLearning, María-Victoria Mateos, 233966

Update on recent smoldering multiple myeloma trials

ESH eLearning, María-Victoria Mateos, 234032